AI-Enabled Lung Assessment Tool for Handheld Ultrasound Gets FDA Nod
The artificial intelligence (AI) powered Auto B-line Counter, which reportedly produces a B-line count from a six-second ultrasound clip, may facilitate more expedient and consistent assessment of abnormal lung function.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Auto B-line Counter (Butterfly Network), a handheld ultrasound tool that may help accelerate assessment of suspected lung function abnormality in patients with conditions ranging from chronic obstructive pulmonary disease (COPD) to COVID-19.
In contrast to traditional manual processes for counting B-lines from lung ultrasound scans, the Auto B-line Counter utilizes deep learning technology that can provide a B-line count from a six-second ultrasound clip, according to the Butterfly Network, the manufacturer of the modality.
Incorporating an instant percent counting technique, Butterfly Network said the algorithm for the Auto B-line Counter accounts for discrete B-lines as well as confluent B-lines by the percentage of occupied rib space.
“Our AI-enabled Auto B-line Counter empowers providers to assess lung conditions faster and with more confidence and in turn will aid in earlier detection, diagnosis, and treatment of cardiovascular diseases, a leading cause of death globally, taking nearly 18 million lives each year,” noted Jonathan Rothberg, Ph.D., the founder and interim chief executive officer of Butterfly Network.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
